Patent 11124567 was granted and assigned to Denali Therapeutics on September, 2021 by the United States Patent and Trademark Office.
In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.